Quick Answer
CollPlant Biotechnologies Ltd reported R&D Expense of $8.19 million for fiscal year 2025.
CollPlant Biotechnologies Ltd R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $8.19M | -22.1% |
| 2024 | $10.52M | +0.3% |
| 2023 | $10.48M | +2.2% |
| 2022 | $10.26M | +34.4% |
| 2021 | $7.63M | +87.7% |
| 2020 | $4.07M | -7.9% |
| 2019 | $4.41M | +13.9% |
| 2018 | $3.88M | +563.9% |
| 2017 | $584.0K | -98.0% |
| 2016 | $29.20M | +27.4% |
| 2015 | $22.92M | — |
- CollPlant Biotechnologies Ltd showed a decrease of -22.1% in R&D Expense compared to the prior fiscal year.
- Over the 2015–2025 period, CollPlant Biotechnologies Ltd’s r&d expense has declined by 64.3% (from $22.92 million to $8.19 million).
- The most recent figure is from CollPlant Biotechnologies Ltd’s fiscal year 2025 report (Form 20-F), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: